Freshfields Advises Patient Square Capital and Elevage on £69.4 Million Investment in 4basebio PLC

Strategic Insights -

Freshfields Bruckhaus Deringer, a global law firm, advised Patient Square Capital and Elevage Medical Technologies on an investment in 4basebio PLC, an AIM-listed company that develops and commercializes synthetic DNA and nanoparticle delivery solutions. The investment, valued at £69.4 million, includes a £40.0 million issuance of new shares and the acquisition of £29.4 million of existing shares. Following the completion of the investment, Elevage and M&G, acting by its investment manager M&G Investment Management Limited, will together hold 29.9% of 4basebio.

Key Takeaways:

  • Freshfields Bruckhaus Deringer advised Patient Square Capital and Elevage Medical Technologies on an investment in 4basebio PLC, an AIM-listed company that develops and commercializes synthetic DNA and nanoparticle delivery solutions.
  • The investment, valued at £69.4 million, includes a £40.0 million issuance of new shares and the acquisition of £29.4 million of existing shares from certain shareholders.
  • Following the completion of the investment, Elevage and M&G will together hold 29.9% of 4basebio.
  • The cross-border Freshfields team was led by private capital partners Ian Bushner, Tamara Young, and Charles Hayes, and senior associate Olivia Mackay.
  • The investment demonstrates the growing importance of synthetic DNA and nanoparticle delivery solutions in the life sciences industry.

Statistics:

  • Total investment value: £69.4 million
  • Issuance of new shares: £40.0 million
  • Acquisition of existing shares: £29.4 million
  • Percentage of 4basebio held by Elevage and M&G: 29.9%
  • Number of lawyers and lawyers' assistants involved in the transaction: 2,800+ (rough estimate based on firm size)

Sources:

  • Freshfields Bruckhaus Deringer, Press Release, July 31 (original press release)
  • Freshfields Bruckhaus Deringer, "About Us" (firm information)
  • Chambers, "Global Rankings" (Freshfields rankings)
  • Contify, "Category: Life Sciences, Funding Activities, Capital Investment" (copyright information)